Penwest Pharmaceuticals Co.
39 Old Ridgebury Road
Suite 11
Danbury,
CT 06810-5120
United States - Map
Phone: 203-796-3700
Fax: 203-794-1393
Web Site: http://www.penw.com
| Penwest Pharmaceuticals Co. develops pharmaceutical products based on drug delivery technologies with focus on products that address disorders of the nervous system. Its proprietary drug delivery technologies include TIMERx, a controlled-release technology; Geminex, a technology enabling drug release at two different rates; SyncroDose, a technology enabling controlled release at the appropriate site in the body; and GastroDose system, a technology enabling drug delivery to the upper gastrointestinal tract. The company offers Opana ER, an oral extended release opioid analgesic for patients with moderate to severe pain requiring continuous opioid treatment using its TIMERx drug delivery technology; and Nifedipine XL for the treatment of hypertension and angina. Its products under development include Nalbuphine ER, a Phase IIa clinical trail product for the treatment of moderate chronic pain; and A0001, a Phase Ib clinical trail product for the treatment of diseases related to the inherited mitochondrial respiratory chain. Penwest Pharmaceuticals Co. has strategic alliance agreement with Endo Pharmaceuticals, Inc. for the development of Opana ER; collaboration and licensing agreement with Edison Pharmaceuticals, Inc. for the development of A0001 and up to one additional drug candidate of Edisons.; and collaboration agreement with Mylan Pharmaceuticals Inc. for the development of Nifedipine XL. It also has a research and development agreement with Otsuka Pharmaceutical Co. Ltd. to develop a formulation of Otsuka compound utilizing the companys TIMERx drug delivery technology. The company was founded in 1991 and is based Danbury, Connecticut. Penwest Pharmaceuticals Co. (NasdaqNM:PPCO) operates independently of Penford Corp. as of August 31, 1998. |
|
| Key Statistics |
| |
| | Pay | Exercised | Ms. Jennifer L. Good , 44
Chief Exec. Officer, Pres and Exec. Director |
$
474.00K |
$
0 | Dr. Anand R. Baichwal Ph.D., 54
Chief Scientific Officer and Sr. VP of Licensing |
$
285.00K |
$
0 | Mr. Thomas R. Sciascia M.D., 56
Chief Medical Officer and Sr. VP |
$
360.00K |
$
0 | Dr. Amale Hawi Ph.D., 55
Sr. VP of Pharmaceutical Devel. |
$
342.00K |
$
0 | Prof. John N. Staniforth B.Sc, Ph.D, MRPharmS, FZS, CChem, FRSC, 55
Consultant |
$
30.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.0899 (3.83%) 
Profile
